US76155X1000
US76155X1000
Revolution Medicines, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 40.67B EUR | 40.12B EUR | 19.47B EUR | 15.69B EUR |
Enterprise Value | 37.57B EUR | 39.95B EUR | 19.18B EUR | 15.47B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -32.55x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 15.6x | 15.4x | 12.98x | 9.62x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -23.22x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -1.75% | -3.96% | -5.51% | -4.56% |